Development of a new method of intranasal injection of GALP regarding clinical application to obese people

Abstract

S D D 星薬科大学・薬学部・運動生理学 ＊1) 昭和大学・医学部・顕微解剖学部門 ＊２) 桐生大学・医療保健学部・栄養学科 ＊3) 昭和大学・歯学部・口腔解剖学 ＊4) 竹ノ谷文子 ＊1,2) ・平子哲史 ＊2) ・影山晴秋 ＊3) ・野中直子 ＊4) ・塩田清二 ＊2) GALP による抗肥満の臨床応用に向けた 点鼻投与法の開発 Development of a new method of intranasal injection of GALP regarding clinical application to obese people Galanin-like peptide (GALP) was discovered in the porcine hypothalamus in 1999 and it was found to be a 60 amino-acid peptide. Administration of GALP is well known to decrease food intake and body weight. In addition, it is also shown to increase core body temperature and energy metabolism after intraventricular infusion. Therefore, GALP may be a potential therapeutic medicine to be sued for the treatment of life-related diseases. This review summarizes the current evidence regarding the function of GALP, particularly in relation to feeding and energy metabolism. Moreover, intranasal administration of GALP is an effective route for delivery to the brain. We have examined the effect of GALP on food intake, body weight and energy metabolism after intranasal infusion which is a clinically viable route of delivery. We will present here that GALP may be used for obese people and also be helpful to overcome lifestyle related diseases in the near future.